Investors are stuck on Ciphergen.
The ProteinChip developer missed a June 23 deadline to lift its market capitalization above the Nasdaq Exchange's minimum requirements, and it now faces the prospect of being delisted.
But shares in Ciphergen have been up 6.2 percent year to date, and up 4.3 percent since May 31, when the company disclosed that its market cap had fallen below the Nasdaq's minimum standard of $50 million for 10 consecutive trading days.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
